Alternative Base Solutions for del Nido Cardioplegia: Composition, Rationale, and Clinical Evidence
1
Issued Date
2026-01-01
Resource Type
eISSN
2753670X
Scopus ID
2-s2.0-105028630011
Journal Title
Interdisciplinary Cardiovascular and Thoracic Surgery
Volume
41
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Interdisciplinary Cardiovascular and Thoracic Surgery Vol.41 No.1 (2026)
Suggested Citation
Kantathut N. Alternative Base Solutions for del Nido Cardioplegia: Composition, Rationale, and Clinical Evidence. Interdisciplinary Cardiovascular and Thoracic Surgery Vol.41 No.1 (2026). doi:10.1093/icvts/ivag019 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114350
Title
Alternative Base Solutions for del Nido Cardioplegia: Composition, Rationale, and Clinical Evidence
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives Del Nido cardioplegia has gained increasing popularity, evolving from its original use in paediatric and congenital heart surgery to widespread adoption in adult cardiac procedures. This review aims to summarize the composition, physiologic rationale, and clinical evidence supporting the use of alternative base solutions in del Nido cardioplegia. Methods A comprehensive literature review was conducted, analyzing experimental, observational, and randomized clinical studies that compared modified del Nido cardioplegia prepared with various alternative crystalloids. Results Evidence demonstrates that del Nido cardioplegia prepared with alternative crystalloids including normal saline, lactated Ringer’s, plain Ringer’s, Isolyte S, Ionosteril, and whole blood provides myocardial protection and postoperative outcomes comparable with Plasma-Lyte A when appropriately buffered and supplemented. Conclusions Alternative base solutions including normal saline, lactated Ringer’s, plain Ringer’s, Isolyte S, Ionosteril, and whole blood represent safe, effective, and cost-efficient substitutes for Plasma-Lyte A in del Nido cardioplegia. Standardized formulations and multicentre randomized studies are warranted to confirm long-term safety and support broader global implementation.